BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024PRNewsWire • 11/16/24
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance RaisedZacks Investment Research • 10/30/24
BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 10/29/24
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and OutlookPRNewsWire • 10/29/24
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ETPRNewsWire • 10/16/24
Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN)Zacks Investment Research • 10/01/24
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains BullishBenzinga • 09/25/24
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society MeetingPRNewsWire • 09/18/24
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 YearsZacks Investment Research • 09/05/24
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial GuidancePRNewsWire • 09/04/24
BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NYPRNewsWire • 08/29/24